<DOC>
	<DOCNO>NCT02602509</DOCNO>
	<brief_summary>The purpose study evaluate bactericidal activity Mycobacterium tuberculosis celecoxib combination establish drug use treat tuberculosis ( TB ) . Pharmacokinetics ( PK ) whole blood bactericidal activity ( WBA ) measure healthy volunteer follow administration study drug alone combination .</brief_summary>
	<brief_title>Evaluating Celecoxib Activity Mycobacterium Tuberculosis : A Whole Blood Bactericidal Activity Study Healthy Volunteers</brief_title>
	<detailed_description>The whole blood bactericidal activity ( WBA ) assay ex vivo model measure combined effect administer drug , host factor strain factor mycobacterial sterilisation . If perform parallel PK measurement , method use evaluate effect drug throughout dose cycle . Celecoxib COX-2 inhibitor immuno-modulatory property important host defence tuberculosis ( TB ) . The aim trial investigate effect WBA manipulation host response TB use celecoxib , combination establish TB drug .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Aged 21 year 60 year old 2 . Male female willing comply study visit procedures 3 . Willing able provide write informed consent 1 . Women currently pregnant breastfeed 2 . Body weight 50kg 3 . Clinical sign active TB opinion investigator 4 . Previous hypersensitivity , intolerance allergy rifampicin , pyrazinamide , COX2 inhibitor , nonsteroidal antiinflammatory drug sulfonamides 5 . Current use drug medication know interaction rifampicin , pyrazinamide celecoxib 6 . Current use use last 2 week nonsteroidal antiinflammatory drug COX2 inhibitor 7 . Current use use last 2 week drug , counter herbal preparation know potential inhibitor inducer cytochrome P450 enzymes 8 . Evidence renal hepatic dysfunction clinically significant deviation normal screen include laboratory determination 9 . Known hepatic disease , recent hepatitis ( within last 6 month ) alcohol abuse 10 . Known cardiovascular disease , heart failure , stroke current cardiovascular risk factor 11 . Known peptic ulcer disease , previous gastrointestinal bleed current risk factor gastrointestinal event 12 . Acute previous gout , acute porphyria 13 . Any significant condition would , opinion investigator , compromise volunteer 's safety outcome trial 14 . Current participation clinical intervention trial research protocol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>